EQS-News: More Impact AG: Prof. Stefan Hegemann appointed as new member of the Supervisory Board
|
EQS-News: More Impact AG
/ Key word(s): Personnel
More Impact AG: Prof. Stefan Hegemann appointed as new member of the Supervisory Board Frankfurt am Main, 02 July 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, announces that the Frankfurt District Court has appointed Prof. Dr. Stefan Hegemann as a new member of the Supervisory Board following a proposal by the company. He succeeds Dr. Karsten Behlke, who has resigned from office to move to the operational business of More Impact AG. Prof. Hegemann will stand for election to the Supervisory Board at the company's upcoming Ordinary General Meeting on August 21, 2025. With his long-standing experience as a medical doctor and his comprehensive scientific know-how, Prof. Hegemann will support More Impact in its future growth. He is a honorary professor of the University of Zurich and is also the founder of the renowned “Balance Clinic”. Prof. Hegemann was head physician at the Department of Otorhinolaryngology and Facial Surgery of the University Hospital Zurich for several years. He also worked at the Johns Hopkins University in Baltimore and the Karlsbad-Langensteinbach Clinic. He completed his medical studies at the University of Essen, the LMU Munich, the McMaster University Hamilton and the University of Cape Town in South Africa. Prof. Hegemann is a member of the Prosper Menière Society, the Association of German-speaking Audiologists and Neurootologists (ADANO) and the Robert Barány Society. He is also a member of both the German Society for ENT and Neurology, Head and Neck Surgery and the Swiss Society for Otorhinolaryngology, Neck and Facial Surgery. In addition, he has been honoured with several accolades, including the ADANO Innovation Award. Dr. Gerald Schüssel, CEO of More Impact AG: "We are very pleased that Prof. Hegemann has agreed to accept the office and to stand for election at the upcoming Ordinary General Meeting. With him, we have gained an excellent physician for our Supervisory Board. Our company will benefit greatly from his know-how and innovative strength in the medical field. At the same time, I am looking forward to the operational cooperation with Dr. Behlke, who has already provided More Impact with valuable impetus as a member of the Supervisory Board." About More Impact AG More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model. Contact – Investor & Media Relations
02.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | More Impact AG |
| Mörfelder Landstraße 277 b | |
| 60598 Frankfurt | |
| Germany | |
| Phone: | +49 69 38076661 |
| E-mail: | info@moreimpactag.de |
| Internet: | https://moreimpactag.de |
| ISIN: | DE000A1PG979, DE000A40ZTM3 |
| WKN: | A1PG97 |
| Listed: | Regulated Unofficial Market in Dusseldorf |
| EQS News ID: | 2163964 |
| End of News | EQS News Service |
|
|
2163964 02.07.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 0,10 | 0,00 | 0,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | 0,00 | -0,37 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | -370,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | 0,00 | -0,81 | 0,00 | 0,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | -810,00 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | 0,00 | -0,81 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -810,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | 0,00 | -0,37 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | 0,00 | 0,00 | -0,01 | -0,02 | -0,02 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Nexia
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| More Impact | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A1PG97 | DE000A1PG979 | AG | 391,53 Mio € | 30.07.2012 | Halten | 9F2C3MM7+X6 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 30,00 | 0,00 | 0,00 | -75,00 | 5,59 | -1.069,76 | 3.954,87 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 29.08.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -8,42% | -29,08% | +50,75% | +50,00% | +20,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
